Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

FDMT 4D Molecular Therapeutics Inc

5,83

0,00 (0,00%)

03 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more 4D Molecular Therapeutics Charts.

4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more 4D Molecular Therapeutics Charts.

News 4D Molecular Therapeutics Inc

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
Montag 16 Dezember 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form 8-K - Current report
Mittwoch 11 Dezember 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 6 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (2 Monate vor) • Edgar (US Regulatory)

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
Donnerstag 14 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 13 November 2024 (2 Monate vor) • Edgar (US Regulatory)

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Mittwoch 13 November 2024 (2 Monate vor) • GlobeNewswire Inc.

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Montag 23 September 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 18 September 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 18 September 2024 (4 Monate vor) • Edgar (US Regulatory)

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
Mittwoch 18 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Weitere 4D Molecular Therapeutics Inc News-Artikel

JP Morgan Chase

Invesco QQQ Trust Series 1

Deutsche Telekom

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen